Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder clinical trials

THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+)

This study looks at how well a new three-in-one inhaler, Trelegy, works compared to a standard two-in-one inhaler for people with severe COPD. We want to see if Trelegy helps patients keep their breathing problems better controlled over a year.